BR9814214A - Composição com ácido azeláico - Google Patents

Composição com ácido azeláico

Info

Publication number
BR9814214A
BR9814214A BR9814214-3A BR9814214A BR9814214A BR 9814214 A BR9814214 A BR 9814214A BR 9814214 A BR9814214 A BR 9814214A BR 9814214 A BR9814214 A BR 9814214A
Authority
BR
Brazil
Prior art keywords
composition
azelaic acid
skin
acid
triacylglycerides
Prior art date
Application number
BR9814214-3A
Other languages
English (en)
Other versions
BR9814214B1 (pt
Inventor
Patrick Franke
Clemens Guenther
Jutta Riedl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR9814214A publication Critical patent/BR9814214A/pt
Publication of BR9814214B1 publication Critical patent/BR9814214B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Abstract

Patente de Invenção: <B>"COMPOSIçãO COM áCIDO AZELáICO"<D>. A invenção refere-se a uma composição terapêutica, que possui os seguintes componentes: ácido azeláico, ácido poliacrílico, triacilglicerídios, propilenoglicol, polissorbatos, lecitina de soja, água e sais. A composição é um hidrogel, que é adequado para o tratamento de rosácea, pele idosa, melasma ou irritações da pele.
BRPI9814214-3A 1997-11-19 1998-11-18 composição com ácido azeláico. BR9814214B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19753044 1997-11-19
US7485098P 1998-02-12 1998-02-12
DE19808086 1998-02-20
PCT/EP1998/007370 WO1999025332A1 (de) 1997-11-19 1998-11-18 Zusammensetzung mit azelainsäure

Publications (2)

Publication Number Publication Date
BR9814214A true BR9814214A (pt) 2000-10-03
BR9814214B1 BR9814214B1 (pt) 2010-07-13

Family

ID=27217979

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9814214-3A BR9814214B1 (pt) 1997-11-19 1998-11-18 composição com ácido azeláico.

Country Status (21)

Country Link
US (1) US6534070B1 (pt)
EP (1) EP1032379B1 (pt)
JP (1) JP3867123B2 (pt)
KR (1) KR100534511B1 (pt)
AT (1) ATE210438T1 (pt)
AU (1) AU743437B2 (pt)
BR (1) BR9814214B1 (pt)
CA (1) CA2311128C (pt)
CZ (1) CZ299116B6 (pt)
DE (2) DE19881737D2 (pt)
DK (1) DK1032379T3 (pt)
ES (1) ES2169566T3 (pt)
HU (1) HU226592B1 (pt)
IL (1) IL136101A (pt)
IS (1) IS2257B (pt)
NO (1) NO327712B1 (pt)
PL (1) PL202454B1 (pt)
PT (1) PT1032379E (pt)
SK (1) SK284338B6 (pt)
TR (1) TR200001393T2 (pt)
WO (1) WO1999025332A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE502004004660D1 (de) * 2003-06-10 2007-09-27 Intendis Gmbh Zusammensetzung aus alkandicarbonsäuren und einem pharmazeutischen wirkstoff
US20050026982A1 (en) * 2003-06-10 2005-02-03 Soenke Johannsen Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient
ES2278115T3 (es) * 2003-10-13 2007-08-01 Zoser B. Nat.Rer.Dr. Salama Composicion farmaceutica que comprende oxoplatino y sus sales.
DE10356288B4 (de) 2003-11-28 2014-04-03 Siemens Aktiengesellschaft Röntgendetektorlade
CA2600054A1 (en) * 2005-03-09 2006-09-21 Combe Incorporated Stable mixed emulsions
EP1926466A2 (en) * 2005-09-19 2008-06-04 Combe Incorporated Stable emulsion systems with high salt tolerance
KR100861978B1 (ko) * 2007-03-22 2008-10-07 한국콜마 주식회사 아젤라산을 이용한 여드름 치료용 화장료 조성물 및 그 제조방법
US8729108B2 (en) * 2008-06-17 2014-05-20 Christopher J Dannaker Waterborne topical compositions for the delivery of active ingredients such as azelaic acid
EP2201930A1 (en) 2008-12-23 2010-06-30 Intendis GmbH Hydrogel composition for the treatment of dermatological disorders
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
PL217786B1 (pl) * 2009-05-28 2014-08-29 P P F Hasco Lek Spółka Akcyjna Żel z kwasem azelainowym i sposób wytwarzania żelu z kwasem azelainowym
BR112012003834A2 (pt) 2009-08-21 2017-08-08 Targeted Delivery Tech Limited métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote
DE102010021671A1 (de) 2010-05-27 2011-12-01 Intendis Gmbh Azelainsäurehaltige Formulierung mit Pigmentzusatz
GB201205642D0 (en) * 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
EP3954361A1 (en) 2015-06-30 2022-02-16 Sequessome Technology Holdings Limited Multiphasic compositions
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3811081A1 (de) 1988-03-30 1989-10-12 Schering Ag Verwendung von topisch applizierbaren praeparaten zur behandlung der altershaut
ATE117665T1 (de) * 1990-11-14 1995-02-15 Oreal Amphiphile, nichtionische derivate des glycerins sowie die entsprechenden zwischenprodukte, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
GB9316323D0 (en) 1993-08-06 1993-09-22 Procter & Gamble Cosmetic compositions
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5547989A (en) 1994-08-19 1996-08-20 Schering-Plough Healthcare Products, Inc. Compositions for treating corns and calluses
US5618522A (en) * 1995-01-20 1997-04-08 The Procter & Gamble Company Emulsion compositions
UY24246A1 (es) 1995-06-06 1996-06-14 Neutrogena Corp Vehiculos tropicos que contienen acido azelaico solubilizado y estabilizado

Also Published As

Publication number Publication date
BR9814214B1 (pt) 2010-07-13
DE19881737D2 (de) 2001-03-22
NO327712B1 (no) 2009-09-14
PL340631A1 (en) 2001-02-12
ATE210438T1 (de) 2001-12-15
EP1032379A1 (de) 2000-09-06
IS2257B (is) 2007-06-15
DE59802473D1 (de) 2002-01-24
PL202454B1 (pl) 2009-06-30
IL136101A (en) 2005-08-31
CZ20001844A3 (cs) 2000-10-11
KR100534511B1 (ko) 2005-12-08
NO20002487L (no) 2000-07-18
CA2311128A1 (en) 1999-05-27
HU226592B1 (en) 2009-04-28
SK284338B6 (sk) 2005-02-04
US6534070B1 (en) 2003-03-18
EP1032379B1 (de) 2001-12-12
AU743437B2 (en) 2002-01-24
AU1755199A (en) 1999-06-07
DK1032379T3 (da) 2002-04-02
JP2001522879A (ja) 2001-11-20
HUP0004375A3 (en) 2006-06-28
ES2169566T3 (es) 2002-07-01
KR20010032229A (ko) 2001-04-16
NO20002487D0 (no) 2000-05-12
PT1032379E (pt) 2002-06-28
TR200001393T2 (tr) 2000-10-23
JP3867123B2 (ja) 2007-01-10
CZ299116B6 (cs) 2008-04-30
CA2311128C (en) 2008-01-29
IL136101A0 (en) 2001-05-20
IS5484A (is) 2000-05-09
WO1999025332A1 (de) 1999-05-27
HUP0004375A2 (hu) 2001-08-28
SK7082000A3 (en) 2001-06-11

Similar Documents

Publication Publication Date Title
BR9814214A (pt) Composição com ácido azeláico
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
BR9916694A (pt) Composição de lenço facial e método de uso parasequestração de irritantes cutâneos de secreçãonasal
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
ATE314067T1 (de) Cannabinol-11-säurederivate als entzündungshemmer und analgetika
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
BR0009211A (pt) Derivados de resorcinol
BR9813549A (pt) Processo para prevenção e tratamento de miocárdio afetado por lesão
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
BR0213410A (pt) Usos farmacêuticos de bisfosfonatos
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
BR0211827A (pt) Uso de inibidores de il-18 em distúrbios de hipersensibilidade
BR9914570A (pt) Processo para o tratamento da esquizofrenia bem como agentes para o emprego neste processo
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INTENDIS GMBH (DE)

Free format text: TRANSFERIDO DE: SCHERING AKTIENGESELLSCHAFT

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/07/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13.07.2020